BCR and chronic myelogenous leukemia, BCR-ABL1 positive: SNIPER(ABL)-2 (Fig. 4), containing imatinib and MeBS to recruit E3 ligase IAP, showed strong BCR-ABL degradation ability and potently inhibited growth of CML K562 cells [72].